CE Facilitation for Local Factories in Egypt: The April 2026 EDA Announcement

1. Key takeaways

On April 16, 2026, the Egyptian Drug Authority issued an announcement granting three exemptions to local factories holding CE certificates: when submitting registration or re-registration dossiers, they are exempt from submitting the reference-country free sale certificate (FSC), stability studies and biocompatibility test reports. The announcement nevertheless preserves one exception: the EDA retains the right to require submission of these documents. The applicable entity is expressly limited to local factories, and they must hold CE certificates.

2. Legal basis

The facilitation measure sits on top of the baseline obligations in the registration guidelines.

3. Expert insights

Insight 1: the exemption precisely targets the three heaviest evidentiary burdens on the local production pathway.

Under the existing rules of GL.CAMD.002, the three hardest items for local factories are: the reference-country FSC (for local manufacturing it is nominally optional, but the absence of an FSC triggers the first submission scenario of Section 6); stability studies (Section 6, item Second requires a real-time study at re-registration, with sealed samples retained until the end of the validity period); and biocompatibility test reports (Section 6, item Fifth requires testing by a recognized entity with ISO/IEC 17025 accreditation). The announcement exempts all three at once, substantially lowering the compliance threshold for localized production.

Insight 2: the clause retaining the right to require submission means the exemption is conditional, not an abolition of duty.

The reservation clause makes the three exemptions a revocable facilitation. When planning localization projects, companies should remain capable of supplying all three documents at any time; quality systems must not be designed on the assumption of a permanent exemption.

Insight 3: the subject limitation to local factories means the pure import pathway does not qualify.

The announcement applies to local factories holding CE certificates. Chinese manufacturers operating through the importing company or Scientific Office pathways under GL.CAMD.002 Sections 4.1 and 4.2.1 do not obtain these three exemptions merely by holding a CE certificate; the Section 4.2.1 requirement for a reference-country FSC for Class IIb and III imported devices remains in force.

Insight 4: the measure aligns with Egypt’s overall localization policy direction.

At the meeting with the EDA Chairman on September 13, 2026, the Egyptian Prime Minister emphasised supporting the localization of medicine and medical supplies production and raising local output in order to reduce import dependence and develop exports. As a practical estimate, policy statements follow the official Egyptian releases. The CE facilitation announcement, the F-Toll contract manufacturing mechanism in Annex 3, the 2-year rectification period in Section 4.2.2, and the export-only certificates in Section 9 together form a complete localization policy toolkit.

Insight 5: the measure stacks with an existing exemption rule.

GL.CAMD.002 Annex 1, item 7(D) already provides that locally manufactured devices with transactions in a reference country need not submit a biocompatibility test report or stability studies at registration or re-registration. The announcement extends that exemption from having reference-country transactions to holding a CE certificate, widening coverage. Both rules coexist, and a company may invoke the more favourable one.

Insight 6: for combinations of Chinese manufacturers and Egyptian local factories, the measure has direct commercial significance.

For Chinese manufacturers, the announcement makes the combination of an Egyptian factory plus a CE certificate the most advantaged configuration in the Egyptian market: it both avoids the committee review applicable to non-reference-country imports (the first scenario of Section 5 covers devices imported from non-reference countries or locally produced, and note that local production remains within that scope) and removes the three heaviest evidentiary items. As a practical estimate, whether local production still goes before the dedicated scientific committee depends on the current guideline and the actual review, and no presumption is made here.

Insight 7: the announcement sits at the EDA announcement layer, where tracking costs are higher than for guidelines.

Unlike EDREX guidelines, which carry reference numbers, versions and effective dates, EDA announcements are identified by publication date and are updated more frequently. Regulatory intelligence mechanisms should treat the EDA website announcement section as a high-frequency tracking target. As a practical estimate, the specific provisions, scope of application and implementing details of this announcement follow the current announcement text on the EDA website.

4. Practical recommendations

The following steps help capture the facilitation without overcommitting to it.

1. Assess the feasibility of the Egyptian local factory plus CE combination: it is among the strongest pathways in the Egyptian market today.
2. Do not apply the exemption to the pure import pathway: the reference-country FSC requirement for Class IIb and III imported devices remains valid.
3. Maintain the capacity to supply the three documents at any time: the exemption can be revoked.
4. Compare with the existing reference-country transaction exemption and invoke the more favourable rule.
5. Plan against the localization toolkit as a whole: the 2-year rectification period, F-Toll and export-only certificates.
6. Set the EDA website announcement section as a high-frequency tracking target.
7. Obtain written confirmation from the EDA on applicability before committing production plans, avoiding schedule decisions based on assumptions.

5. Verification checklist

• □ The entity is a local factory and holds a CE certificate
• □ The three exemptions (reference-country FSC / stability studies / biocompatibility test reports) are claimed in the dossier
• □ The capacity to supply the three documents at any time is preserved (the exemption is revocable)
• □ The existing reference-country transaction exemption has been compared and the more favourable option selected
• □ The localization toolkit (2-year rectification period / F-Toll / export-only certificates) is included in planning
• □ The EDA website announcement section is set as a high-frequency tracking item
• □ Applicability has been confirmed in writing with the EDA

Regulatory information verified as of October 29, 2026. The facilitation measures in this article follow the original EDA announcement of April 16, 2026; the baseline obligations follow the current text of EDREX: GL.CAMD.002 Version 2, Sections 4.2.2 and 6, and GL.CAMD.09 Version 2.

• Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
• Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.